Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Cancer Medicine|July 6, 2023
Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemiaYilin Chen, Na Xu, Yunfan Yang, et al.
British Journal of Haematology|March 11, 2022
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm)Hui Wei, Chunlin Zhou, Bingcheng Liu, et al.
Journal of Hematology & Oncology|August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology|September 7, 2020
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemiaRunxia Gu, Fang Liu, Dehui Zou, et al.
Annals of Hematology|June 5, 2021
Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter studyXuelin Dou, Fangyuan Zheng, Liqiang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2020
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd StudyLi Zhang, Li Meng, Bingcheng Liu, et al.
Haematologica|October 16, 2025
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluationMengyao Yuan, Li Zhou, Weiming Li, et al.
Haematologica|April 30, 2025
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemiaXiaoshuai Zhang, Yunfan Yang, Bingcheng Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 9